Nonsense mutation Duchenne muscular dystrophy (nmDMD) patients living in the European Union may soon experience relief from their condition due to the European Commission granting PTC Therapeutics, Inc. conditional marketing for Translarna™ (ataluren). PTC Therapeutics may now market Translarna in the 28 Member States of…
PTC Therapeutics’ Translarna for nmDMD is Conditionally Approved in European Union
Recent Posts
- Oral ALS treatment lowers toxic protein levels, extends survival
- Ex-NFL running back says he ‘chose to fight’ after his ALS diagnosis
- New ALS treatment enters human testing in global program
- Accessible travel granted my late husband normalcy, independence
- Amylyx advancing ALS treatment in trial after early safety data is positive